BioCentury
ARTICLE | Company News

Xyphos, Parker Institute steer next-gen CAR T therapies into solid tumors

October 18, 2018 2:01 PM UTC

Xyphos Biosciences Inc. (South San Francisco, Calif.) will partner with the Parker Institute for Cancer Immunotherapy to develop CAR Ts using Xyphos' convertibleCAR platform. Xyphos President and CEO Jim Knighton told BioCentury the research will focus primarily on treating solid tumors, which traditional CAR Ts have difficulty entering.

Xyphos uses its technology to develop therapies comprising universal CAR Ts and a bispecific antibody designed to bind, activate and tow those CAR Ts into solid tumors against a tumor-specific target...